Form 4: Tenaya Therapeutics Director Acquires Stock Options

Catherine Stehman-Breen, a director of Tenaya Therapeutics, Inc., was granted stock options to purchase 34,000 shares of common stock.

Summary

• On October 18, 2024, Catherine Stehman-Breen, a director of Tenaya Therapeutics, Inc. (TNYA), acquired stock options.
• The options grant the right to buy 34,000 shares of Tenaya Therapeutics' common stock at an exercise price of $2.04 per share.
• The options were granted under the company's 2021 Equity Incentive Plan.
• The options will vest in full on May 31, 2025, or earlier if the next annual meeting of stockholders occurs before that date, contingent on continued service to the company.
• The options expire on October 17, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative on its own.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Option grants are a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates